GENERAL

SELLAS Reports Positive Phase 3 Cancer Vaccine Trial Results

18/11/2026 04:21 PM

KUALA LUMPUR, Nov 18 (Bernama) -- SELLAS Life Sciences Group Inc (SELLAS), a late-stage clinical biopharmaceutical company, has announced positive topline results from the pivotal randomised Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukaemia (AML).

The trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission or complete remission with insufficient platelet recovery following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.

“We are deeply grateful to the patients and their families, investigators, clinical teams, and everyone who contributed to REGAL over the course of this study. Their commitment has helped make this important milestone possible,” said SELLAS President and Chief Executive Officer, Angelos Stergiou.

The REGAL trial met its primary endpoint of overall survival (OS), with GPS demonstrating a statistically significant and clinically meaningful improvement compared with the investigator's choice of best available treatment (BAT).

SELLAS said in a statement that GPS demonstrated a 41 per cent reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035, while median OS was 24.0 months compared with 14.7 months for patients receiving the BAT.

GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate (grade 1/2), most commonly consisting of local injection site reactions.

SELLAS said both treatment arms were well balanced for prognostic stratification factors, while the number of patients who proceeded to haematopoietic stem cell transplantation was limited and equally distributed between the study and control arms.

The company plans to meet with the United States Food and Drug Administration (FDA) to discuss an accelerated filing strategy and advance preparations for a Biologics License Application (BLA) submission for GPS in the first half of 2027.

-- BERNAMA


BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires; www.bernama.com; BERNAMA TV on Astro 502, unifi TV 631 and MYTV 121 channels and BERNAMA Radio on FM93.9 (Klang Valley), FM107.5 (Johor Bahru), FM107.9 (Kota Kinabalu) and FM100.9 (Kuching) frequencies.

Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial

© 2026 BERNAMA   • Disclaimer   • Privacy Policy   • Security Policy